.Anavex Life Sciences’ lead asset has failed to significantly improve disease characteristics in a pediatric Rett syndrome trial, with the company pointing the blame toward a high placebo effect.The New York City-based biotech's stock cratered 30% since the data was shared earlier today, tumbling from $9.32 per share at market close Friday to $6.55 as of 10:30 a.m. ET.
.Anavex Life Sciences’ lead asset has failed to significantly...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.64 |
Change
0.920(4.44%) |
Mkt cap ! $2.763B | |||
| Open | High | Low | Value | Volume |
| $20.86 | $21.64 | $20.56 | $19.10M | 890.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $21.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.64 | 588 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.48 |
Change
0.920 ( 3.36 %) |
||||
| Open | High | Low | Volume | ||
| $20.87 | $21.61 | $20.55 | 164887 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| NEU (ASX) Chart |